Navigation Links
Cancer Cure Coalition Proposes Major Changes at the FDA
Date:2/21/2008

PALMS BEACH GARDENS, Fla., Feb. 21 /PRNewswire/ -- Flawed policies and bad decisions at the FDA have contributed to an escalation of the cost of clinical trials which now take an average of one billion dollars and require 10 years for approval. This has delayed and even prevented the availability of many promising treatment options, resulting in increased death and suffering for patients and greatly increasing the cost of medical treatment in the United States.

It's time to reform the FDA. It is failing in its mission and greatly harming the United States.

The FDA itself has acknowledged that it cannot do the job given to it by Congress and that it is failing in its mission. In a November 2007 report entitled "FDA Science and Mission at Risk," prepared for the FDA by its own subcommittee on Science and Technology, it states:

"The FDA cannot fulfill its mission because:

1.2.1) Its scientific base has eroded and its scientific organizational structure is weak.

1.2.2) Its scientific workforce does not have sufficient capacity and capability.

1.2.3) Its information technology (IT) infrastructure is inadequate."

It further states that "the lack of new science capability/capacity places the FDA mission at risk for those many products at the leading edge of innovation."

Proposals have been made by many that substantial additional funding be given to the FDA. There has even been a foundation, A Coalition for a Stronger FDA, formed to achieve this end. But as Dr. Henry I. Miller of the Hoover Institution pointed out in his book "To America's Health / A Proposal to Reform the Food and Drug Administration," and also in a letter to The New York Times published on February 10, 2008, additional resources alone are not enough. He stated, "the agency's most significant problems are mismanagement and a culture that is excessively risk-averse. Repeatedly accused (unjustly) of not being sufficiently concerned about drug safety, regulators keep raising the bar for approval, especially for innovative, high-tech products."

We at the Cancer Cure Coalition agree with Dr. Miller that "What the FDA needs is competent management, discipline in the ranks, more effective risk- benefit balancing, a commitment to permitting patients to assume more responsibility for the risk of medicines, and the banishment of politics from regulatory decisions and policy."

We think that reform is needed as soon as possible, and we propose the following steps be taken:

1. Substantial additional funding should be given to the FDA to help it fulfill the increase in duties placed upon it by the Congress.

2. The "Food" division should be separated from the "Drug" division. Insuring the safety of food for the United States is an enormous responsibility and would be best performed by an agency dedicated to that purpose.

3. A special study should be made by an independent organization to make sure that the FDA has competent management. Those managers who are incompetent should be replaced. In the "Drug" division, management is needed that will recognize the needs of the patients and that will apply effective risk-benefit balancing.

4. Consideration should be given to using certified non-governmental agencies to perform the oversight of drug testing and the review of new drug applications. This would reduce cost while improving the quality of the review process.

Unless we move for reform now, the FDA will continue to harm the interests of patients, our health industry and the economy of the United States.

Contact:

Charles A. Reinwald, Chairman

Charles Reinwald, Jr., President

Cancer Cure Coalition

561-747-2174

E-mail: cancercurecoal@aol.com

http://www.cancercurecoalition.org

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Cancer Cure Coalition
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. Diagnostic Center for Disease: Prostate Biopsy Spreads Prostate Cancer Cells
4. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
5. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
8. Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
9. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
10. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
11. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):